BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Sorafenib suppresses STAT5 to inhibit MCL1 (MCL1 apoptosis regulator, BCL2 family member), which overcomes imatinib resistance in CML cells [29].